Home
VERA
VERA News

Latest Vera Therapeutics Inc. (VERA) News on October 27, 2025

MT Newswires

4 months ago

Vera Therapeutics Insider Bought Shares Worth $5,277,311, According to a Recent SEC Filing

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

5 months ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

5 months ago

Wedbush Cuts Price Target on Vera Therapeutics to $23 From $32, Keeps Neutral Rating

Biotech Stock Vera Is Slumping After Monster Gain

Barrons.com

5 months ago

Biotech Stock Vera Is Slumping After Monster Gain

MT Newswires

5 months ago

Top Premarket Decliners

Investing.com

5 months ago

Vera Therapeutics stock sinks following competitor’s successful trial

Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

GlobeNewswire

5 months ago

Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

MT Newswires

5 months ago

Vera Therapeutics Receives Up to $500 Million in New Credit Facility

Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans

GlobeNewswire

5 months ago

Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans

Why Vera Therapeutics, Inc. (VERA) Skyrocketed On Monday

Insider Monkey

5 months ago

Why Vera Therapeutics, Inc. (VERA) Skyrocketed On Monday

MT Newswires

5 months ago

Top Midday Gainers

MT Newswires

5 months ago

Wedbush Raises Price Target on Vera Therapeutics to $32 From $26, Maintains Neutral Rating

MT Newswires

5 months ago

Scotiabank Adjusts Price Target on Vera Therapeutics to $65 From $55, Maintains Outperform Rating

MT Newswires

5 months ago

Vera Therapeutics Says Trial of Kidney Disease Drug Achieves Primary Endpoint; Shares Jump

MT Newswires

5 months ago

Top Premarket Gainers

Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy

GlobeNewswire

5 months ago

Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

6 months ago

Vera Therapeutics' Q1 Net Loss Widens

Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

GlobeNewswire

6 months ago

Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

7 months ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch

Benzinga

7 months ago

Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch

Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN

GlobeNewswire

7 months ago

Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

8 months ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

8 months ago

Wedbush Adjusts Price Target on Vera Therapeutics to $34 From $38, Maintains Neutral Rating

Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

GlobeNewswire

8 months ago

Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

MT Newswires

8 months ago

Vera Therapeutics 2024 Loss Widens

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire

8 months ago

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

8 months ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

9 months ago

Wolfe Research Initiates Coverage on Vera Therapeutics With Outperform Rating, $49 Price Target

MT Newswires

9 months ago

Goldman Sachs Initiates Vera Therapeutics at Buy With $58 Price Target

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

9 months ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

9 months ago

Vera Therapeutics Acquires Global Rights to Dual BAFF/APRIL Inhibitor

Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor

GlobeNewswire

9 months ago

Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor

Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

10 months ago

Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

MT Newswires

10 months ago

Vera Therapeutics Insider Sold Shares Worth $753,680, According to a Recent SEC Filing

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer

GlobeNewswire

a year ago

Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet

Zacks

a year ago

Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet

Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study

GlobeNewswire

a year ago

Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study

Vera Therapeutics to Participate at Upcoming Investor Conferences

GlobeNewswire

a year ago

Vera Therapeutics to Participate at Upcoming Investor Conferences

Vera Therapeutics to Participate at Upcoming Investor Conferences

GlobeNewswire

a year ago

Vera Therapeutics to Participate at Upcoming Investor Conferences

MT Newswires

a year ago

Wedbush Raises Vera Therapeutics' Price Target to $38 From $30, Maintains Neutral rating

MT Newswires

a year ago

Vera Therapeutics Shares Rise After Q3 Results

Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

GlobeNewswire

a year ago

Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

GlobeNewswire

a year ago

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

Vera Therapeutics price target raised to $64 from $56 at Guggenheim

TipRanks

a year ago

Vera Therapeutics price target raised to $64 from $56 at Guggenheim

Vera Therapeutics Breaks Out On Promising Results For Kidney Drug

Investor's Business Daily

a year ago

Vera Therapeutics Breaks Out On Promising Results For Kidney Drug

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

GlobeNewswire

a year ago

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

MT Newswires

a year ago

Vera Therapeutics Shares Jump After Supportive Data From Phase 2b Trial of Kidney Disease Drug Candidate

Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years

Benzinga

a year ago

Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years

Vera Therapeutics Eyes Breakout On Promising Results For Kidney Drug

Investor's Business Daily

a year ago

Vera Therapeutics Eyes Breakout On Promising Results For Kidney Drug

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

GlobeNewswire

a year ago

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

MT Newswires

a year ago

Scotiabank Initiates Vera Therapeutics at Sector Outperform

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

a year ago

Vera Therapeutics Expands Development of Kidney Disease Drug Pipeline

Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024

GlobeNewswire

a year ago

Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024

Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases

GlobeNewswire

a year ago

Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases

Is Vera Therapeutics Inc. (VERA) the Best Performing Small-Cap Stock in 2024?

Insider Monkey

a year ago

Is Vera Therapeutics Inc. (VERA) the Best Performing Small-Cap Stock in 2024?

Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024

GlobeNewswire

a year ago

Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024

Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN

GlobeNewswire

a year ago

Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics, Inc. (VERA): Among the Best Mid-Cap Healthcare Stocks To Buy Now

Insider Monkey

a year ago

Vera Therapeutics, Inc. (VERA): Among the Best Mid-Cap Healthcare Stocks To Buy Now

Adobe Stock Added to JP Morgan Focus List. Here’s Why.

Barrons.com

a year ago

Adobe Stock Added to JP Morgan Focus List. Here’s Why.

Adobe and 2 More Stocks Added to JP Morgan Focus List. Here’s Why.

Barrons.com

a year ago

Adobe and 2 More Stocks Added to JP Morgan Focus List. Here’s Why.

Vera Therapeutics to Participate at September Investor Conferences

GlobeNewswire

a year ago

Vera Therapeutics to Participate at September Investor Conferences

Vera Therapeutics, Inc.'s (NASDAQ:VERA) Intrinsic Value Is Potentially 88% Above Its Share Price

Simply Wall St.

a year ago

Vera Therapeutics, Inc.'s (NASDAQ:VERA) Intrinsic Value Is Potentially 88% Above Its Share Price

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

a year ago

Wedbush Cuts Vera Therapeutics' Price Target to $30 From $32, Maintains Neutral rating

Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

GlobeNewswire

a year ago

Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

a year ago

Vera Therapeutics Appoints David Johnson as Chief Operating Officer

Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer

GlobeNewswire

a year ago

Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer

Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

GlobeNewswire

a year ago

Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire

a year ago

Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

a year ago

Vera Therapeutics Gets FDA Breakthrough Therapy Designation for Immunoglobulin A Nephropathy Treatment

Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)

GlobeNewswire

a year ago

Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)

Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

GlobeNewswire

a year ago

Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

MT Newswires

a year ago

Vera Therapeutics Insider Sold Shares Worth $1,304,435, According to a Recent SEC Filing

MT Newswires

a year ago

Wedbush Adjusts Vera Therapeutics' PT to $32 From $34, Keeps Neutral Rating

Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

GlobeNewswire

a year ago

Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics, Inc.'s (NASDAQ:VERA) high institutional ownership speaks for itself as stock continues to impress, up 5.0% over last week

Simply Wall St.

a year ago

Vera Therapeutics, Inc.'s (NASDAQ:VERA) high institutional ownership speaks for itself as stock continues to impress, up 5.0% over last week

Health Care Roundup: Market Talk

The Wall Street Journal

2 years ago

Health Care Roundup: Market Talk

Could This Stock Be the Next Biotech Buyout?

Motley Fool

2 years ago

Could This Stock Be the Next Biotech Buyout?

Insider Sells at Vera Therapeutics Inc: SVP, Finance, Chief Accounting Officer Joseph Young ...

GuruFocus.com

2 years ago

Insider Sells at Vera Therapeutics Inc: SVP, Finance, Chief Accounting Officer Joseph Young ...

Vertex Pharmaceuticals to buy Alpine Immune Sciences in $4.9B deal

Yahoo Finance Video

2 years ago

Vertex Pharmaceuticals to buy Alpine Immune Sciences in $4.9B deal

ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors

Barrons.com

2 years ago

ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors

Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress

GlobeNewswire

2 years ago

Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire

2 years ago

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference

GlobeNewswire

2 years ago

Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference

Estimating The Fair Value Of Vera Therapeutics, Inc. (NASDAQ:VERA)

Simply Wall St.

2 years ago

Estimating The Fair Value Of Vera Therapeutics, Inc. (NASDAQ:VERA)

Wall Street Analysts Think Dave & Buster's (PLAY) Is a Good Investment: Is It?

Zacks

2 years ago

Wall Street Analysts Think Dave & Buster's (PLAY) Is a Good Investment: Is It?

Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

GlobeNewswire

2 years ago

Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Leslie’s, Inc. Announces First Quarter Fiscal 2024 Financial Results

GlobeNewswire

2 years ago

Leslie’s, Inc. Announces First Quarter Fiscal 2024 Financial Results

Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock

GlobeNewswire

2 years ago

Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock

Factors Setting the Tone for Vista Outdoor (VSTO) Q3 Earnings

Zacks

2 years ago

Factors Setting the Tone for Vista Outdoor (VSTO) Q3 Earnings

Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock

GlobeNewswire

2 years ago

Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock

Share on Social Networks: